Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Istituto Nazionale Tumori Irccs - Fondazione G Pascale manages a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The organization currently has 2 pending office actions being reviewed by the patent office. These 2 pending office actions are distributed across 2 distinct examiners. This distribution indicates that each of the 2 distinct examiners is currently handling a single matter for the institution.
The prosecution activity is situated within 1 distinct art unit. DAWANNA SHAR-DAY WHITE is identified as the busiest examiner for this portfolio, currently overseeing 1 pending office action. This workload for DAWANNA SHAR-DAY WHITE represents a portion of the total pending matters for the organization. The concentration of the portfolio within 1 distinct art unit suggests that the filings are located within a particular technical field.
For practitioners, the presence of 2 pending office actions across 2 examiners and 1 art unit defines the current interaction with the USPTO. The fact that the busiest examiner handles 1 pending office action shows how the work is divided. Prosecution within a single art unit may result in the application of similar examination standards across the active cases in the portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| §103 only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STEPHENS, AMELIA CAROLE | 1 | 85.7% | +33.3% |
| WHITE, DAWANNA SHAR-DAY | 1 | 62.5% | +23.3% |
| JONES, DAMERON LEVEST | 1 | 67.7% | +31.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18854096 | MICROBIOTA ANALOGS OF TUMOR ASSOCIATED ANTIGENS AND USES THEREOF | STEPHENS, AMELIA CAROLE | — |
| 18853315 | COMBINATION OF HDAC INHIBITORS AND STATINS FOR USE IN THE TREATMENT OF PANCREATIC CANCER | WHITE, DAWANNA SHAR-DAY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17789398 | RADIOLABELED PEPTIDES FOR NON-INVASIVE DIAGNOSIS AND TREATMENT OF CXCR4 EXPRESSING TUMORS | JONES, DAMERON LEVEST | 5d |
| 18854096 | MICROBIOTA ANALOGS OF TUMOR ASSOCIATED ANTIGENS AND USES THEREOF | STEPHENS, AMELIA CAROLE | — |
| 18853315 | COMBINATION OF HDAC INHIBITORS AND STATINS FOR USE IN THE TREATMENT OF PANCREATIC CANCER | WHITE, DAWANNA SHAR-DAY | — |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18854096 | MICROBIOTA ANALOGS OF TUMOR ASSOCIATED ANTIGENS AND USES THEREOF | STEPHENS, AMELIA CAROLE | 1645 | §101§102§103§112 | Non-Final OA | — | Pending | Oct 04, 2024 |
| 18853315 | COMBINATION OF HDAC INHIBITORS AND STATINS FOR USE IN THE TREATMENT OF PANCREATIC CANCER | WHITE, DAWANNA SHAR-DAY | — | §103§112 | Non-Final OA | — | Pending | Oct 01, 2024 |
| 17789398 | RADIOLABELED PEPTIDES FOR NON-INVASIVE DIAGNOSIS AND TREATMENT OF CXCR4 EXPRESSING TUMORS | JONES, DAMERON LEVEST | 1618 | §103 | Final Rejection | 5d | Pending | Jun 27, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial